Claims
- 1. A kit for the isolation and subsequent qualitative or quantitative characterization of target biomolecules present in biological fluid comprising:at least one MSIA-Tip having an affinity reagent present within the tip, at least one internal reference standard of predetermined concentration, and at least one mass spectrometer target.
- 2. The kit according to claim 1 wherein the affinity reagent further comprises an affinity ligand, said affinity ligand further comprises anti-human β-2-microglobulin antibody.
- 3. The kit according to claim 1 wherein the internal reference standard is an internal reference standard that shares sequence homology with the target biomolecule.
- 4. The kit according to claim 3 wherein the internal reference standard that shares sequence homology with the target biomolecule is selected from the group comprising enzymatic/chemically-modified versions of the target biomolecule, truncated/extended recombinant forms of the target biomolecules, the target biomolecule recombinantly expressed in isotopically-enriched media, and the target biomolecule from a different biological species.
- 5. The kit according to claim 3 wherein the internal reference standard that shares sequence homology with the target biomolecule is equine β-2-microglobulin.
- 6. The kit according to claim 2 wherein the internal reference standard is an internal reference standard that shares sequence homology with the target biomolecule.
- 7. The kit according to claim 6 wherein the internal reference standard that shares sequence homology with the target biomolecule is selected from the group comprising enzymatic/chemically-modified versions of the target biomolecule, truncated/extended recombinant forms of the target biomolecules, the target biomolecule recombinantly expressed in isotopically-enriched media, and the target biomolecule from a different biological species:
- 8. The kit according to claim 6 wherein the internal reference standard that shares sequence homology with the target biomolecule is equine β-2-microglobulin.
- 9. A method for the isolation and subsequent qualitative characterization of target biomolecules present in biological fluid comprising the steps of:
a. providing a MSIA-Tip having an affinity reagent present, b. separating and concentration the target biomolecule directly from the biological fluid by flowing a volume of the biological fluid through the MSIA-Tip, thereby binding the target biomolecules to the affinity reagent, c. cluting the target biomolecules onto a mass spectrometer target, d. performing mass spectrometric analysis on the target biomolecules in order to qualitatively determine the presence or absence of the target biomolecule in the biological fluid.
- 10. The method according to claim 9 wherein the affinity reagent further comprises an affinity ligand, said affinity ligand further comprises anti-human β-2-microglobulin antibody.
- 11. The method according to claim 9 wherein the qualitative determination further determines the presence of mass shifted variants of the target biomolecule.
- 12. The method according to claim 10 wherein the qualitative determination further determines the presence of mass shifted variants of the target biomolecule.
- 13. A method for the isolation and subsequent quantitative characterization of target biomolecules present in biological fluid comprising the steps of:
a. adding a known amount of internal reference standard of predetermined concentration to a sample of the biological fluid, b. providing a MSIA-Tip having an affinity reagent present, c. flowing a volume of the biological fluid through the pipettor tip, thereby binding the target biomolecules to the affinity reagent, d. eluting the target biomolecules to a mass spectrometer target, e. performing mass spectrometric analysis on the target biomolecules in order to quantitatively determine the concentration of the target biomolecule in the biological fluid.
- 14. The method according to claim 13 wherein the affinity reagent further comprises an affinity ligand, said affinity ligand further comprises anti-human β-2-microglobulin antibody.
- 15. The method according to claim 13 wherein the internal reference standard is an internal reference standard that shares sequence homology with the target biomolecule.
- 16. The method according to claim 15 wherein the internal reference standard that shares sequence homology with the target biomolecule is selected from the group comprising enzymatic/chemically-modified versions of the target biomolecule, truncated/extended recombinant forms of the target biomolecules, the target biomolecule recombinantly expressed in isotopically-enriched media, and the target biomolecule from a different biological species.
- 17. The method according to claim 15 wherein the internal reference standard that shares sequence homology with the target biomolecule is equine β-2-microglobulin.
- 18. The method according to claim 14 wherein the internal reference standard is an internal reference standard that shares sequence homology with the target biomolecule.
- 19. The method according to claim 18 wherein the internal reference standard that shares sequence homology with the target biomolecule is selected from the group comprising enzymatic/chemically-modified versions of the target biomolecule, truncated/extended recombinant forms of the target biomolecules, the target biomolecule recombinantly expressed in isotopically-enriched media, and the target biomolecule from a different biological species.
- 20. The method according to claim 18 wherein the internal reference standard that shares sequence homology with the target biomolecule is equine β-2-microglobulin.
- 21. The method according to claim 13 wherein the quantitative determination further determines the concentration of mass shifted variants of the target biomolecule.
- 22. The method according to claim 14 wherein the quantitative determination further determines the concentration of mass shifted variants of the target biomolecule.
- 23. The method according to claim 15 wherein the quantitative determination further determines the concentration of mass shifted variants of the target biomolecule.
- 24. The method according to claim 16 wherein the quantitative determination further determines the concentration of mass shifted variants of the target biomolecule.
- 25. The method according to claim 17 wherein the quantitative determination further determines the concentration of mass shifted variants of the target biomolecule.
- 26. The method according to claim 18 wherein the quantitative determination further determines the concentration of mass shifted variants of the target biomolecule.
- 27. The method according to claim 19 wherein the quantitative determination further determines the concentration of mass shifted variants of the target biomolecule.
- 28. The method according to claim 20 wherein the quantitative determination further determines the concentration of mass shifted variants of the target biomolecule.
Parent Case Info
[0001] This application is a continuation-in-part of pending application Ser. No. 09/024,988 filed on Feb. 17, 1998, which was a continuation of original application Ser. No. 08/449,903, which was filed on May 23, 1995, now abandoned, the disclosure of which is incorporated herein by reference.
Continuations (1)
|
Number |
Date |
Country |
Parent |
08449903 |
May 1995 |
US |
Child |
09024988 |
Feb 1998 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09024988 |
Feb 1998 |
US |
Child |
09855143 |
May 2001 |
US |